KILITCH

Kilitch Drugs(I) Share Price

₹323.70 +5.6 (1.76%)

21 Dec, 2024 18:46

SIP TrendupStart SIP in KILITCH

Start SIP

Performance

  • Low
  • ₹312
  • High
  • ₹351
  • 52 Week Low
  • ₹300
  • 52 Week High
  • ₹470
  • Open Price₹318
  • Previous Close₹318
  • Volume39,659

Investment Returns

  • Over 1 Month + 3.24%
  • Over 3 Month -11.91%
  • Over 6 Month -1.49%
  • Over 1 Year -6.74%
SIP Lightning

Smart Investing Starts Here Start SIP with Kilitch Drugs(I) for Steady Growth!

Invest Now

Kilitch Drugs(I) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 31.6
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 521
  • P/B Ratio
  • 3
  • Average True Range
  • 14.1
  • EPS
  • 10.24
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.49
  • RSI
  • 51.1
  • MFI
  • 78.15

Kilitch Drugs(I) Financials

Kilitch Drugs(I) Technicals

EMA & SMA

Current Price
₹323.70
+ 5.6 (1.76%)
pointer
  • stock-down_img
  • Bullish Moving Average 9
  • stock-up_img
  • Bearish Moving Average 7
  • 20 Day
  • ₹322.67
  • 50 Day
  • ₹324.46
  • 100 Day
  • ₹330.60
  • 200 Day
  • ₹331.03

Resistance and Support

328.93 Pivot Speed
  • R3 384.82
  • R2 367.93
  • R1 345.82
  • S1 306.82
  • S2 289.93
  • S3 267.82

What's your outlook on Kilitch Drugs(I)?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kilitch Drugs India has an operating revenue of Rs. 157.54 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Kilitch Drugs(I) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-08 Quarterly Results
2024-05-27 Quarterly Results
2024-02-08 Quarterly Results
2023-11-09 Quarterly Results

Kilitch Drugs(I) F&O

Kilitch Drugs(I) Shareholding Pattern

69.23%
0%
0%
25.1%
5.67%

About Kilitch Drugs(I)

  • NSE Symbol
  • KILITCH
  • BSE Symbol
  • 524500
  • Managing Director
  • Mr. Mukund P Mehta
  • ISIN
  • INE729D01010

Similar Stocks to Kilitch Drugs(I)

Kilitch Drugs(I) FAQs

Kilitch Drugs(I) share price is ₹323 As on 21 December, 2024 | 18:32

The Market Cap of Kilitch Drugs(I) is ₹520.6 Cr As on 21 December, 2024 | 18:32

The P/E ratio of Kilitch Drugs(I) is 31.6 As on 21 December, 2024 | 18:32

The PB ratio of Kilitch Drugs(I) is 3 As on 21 December, 2024 | 18:32

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23